Premium
Chemosensitivity testing of human solid tumors. A review of 1582 assays with 258 clinical correlations
Author(s) -
Bertelsen Carl A.,
Sondak Ver K.,
Mann Barry D.,
Korn Edward L.,
Kern David H.
Publication year - 1984
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19840315)53:6<1240::aid-cncr2820530604>3.0.co;2-y
Subject(s) - clonogenic assay , chemosensitivity assay , in vivo , medicine , in vitro , histology , cancer , agar , pathology , cancer research , biology , microbiology and biotechnology , biochemistry , genetics , bacteria
To improve clinical interpretation and use of in vitro clonogenic assay results, the authors reviewed their experience to date with chemosensitivity testing of over 1500 solid tumors. All clonogenic assays were performed using a double‐layer‐soft‐agar system with continuous exposure of cells to one concentration of standard anticancer drugs. Significant growth was defined as > 30 colonies/control plate. Clinical responses were determined according to standard criteria. Data were analyzed using two different criteria of in vitro sensitivity (>50% and >75% inhibition of colony formation) and independently for each histologic type of tumor. Overall, 68% of specimens plated produced significant growth in vitro. Cloning ability varied from 57% to 82% depending on tumor histology. The assay was 57% reliable for predicting in vivo sensitivity, and 92% reliable for in vivo resistance. Predictive accuracy for sensitivity varied from 30% to 86%, depending on the tumor histology. Use of > 50% ICF (inhibition of colony formation) as criteria for differentiating sensitivity from resistance proved most reliable, although criteria should be individualized for each tumor type to maximize predictive accuracy. Cancer 53:1240‐1245, 1984.